small steps great leaps
EXSURGO IS RAPIDLY EXPANDING THE GLOBAL DATABASE OF QUALITY CLINICAL TRIALS AND STUDIES TO CONFIRM THE EFFECTIVENESS OF ITS TECHNOLOGIES FOR A RANGE OF NEUROLOGICALLY-RELATED CONDITIONS, PRIOR TO COMMERCIAL ROLLOUT.
For sales enquiries
Chronic Pain Study (UK)
A recent UK study has confirmed the exciting potential of Exsurgo’s breakthrough treatment for chronic pain management.
In the UK study, conducted from mid 2020 until early 2021, patients reported significant reductions in their levels of pain, anxiety and depression. At the same time, they reported improvements in sleep, mood and quality of life. Furthermore, the improvements from the eight weeks of neurofeedback training were sustained at follow up points – 4, 12 and 26 weeks. The full results of the trial are expected to be published shortly in a medical journal.
The UK study was intentionally small-scale, involving 16 patients, to serve as a proof-of-concept for the Axon system and lay the groundwork for further research. A much larger clinical trial is due to start in New Zealand shortly.
An EEG is a test that measures the electrical activity in your brain by measuring impulses using electrodes placed on the scalp. An EEG can find changes in brain activity that might be useful in diagnosing brain disorders, especially epilepsy or another seizure disorder. Discover how Exsurgo’s Axon technology is transforming the EEG process.
Neurotherapy or neurofeedback is a type of rehabilitation therapy designed to teach the brain to respond differently to triggers. By measuring brain activity levels using EEG technology and responding to it, neurofeedback therapy can be a powerful tool to help reinforce positive behaviour and habits. Discover how Exsurgo’s Axon technology can help.
Patients suffering from issues such as stroke, cardiac arrest, or major surgery often have to go through Rehabilitation Therapy. There are three main types of rehabilitation therapy: occupational, physical, and speech therapy. The aim of Rehabilitation Therapy is to help patients get back to a relatively normal, independent, and high standard of living free from pain, impairments, or addictions.
Of participants reported an improvement in pain*
Of participants achieved a clinically relevant pain reduction (i.e. of at least 30%, considered to be a clinically significant threshold)#
Of participants reported an improvement in sleep, mode and quality of life*
Of participants reported an improvement in anxiety*
Of participants reported an improvement in depression^
* Based on patient VSR (verbal self-reporting) methodology.
#Based on VNS (Visual Numerical Scale) methodology.
^ Based on HADS (Hospital Anxiety and Depression Scale). Prior to Axon treatment 10 out of 16 participants presented with anxiety, and 6 out of 16 with depression.